Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Rossi

Showing results (381-390 of 504) with videos related to

Pageof 51
Sort By:
British Journal of Haematology|March 17, 2010
Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphomaAndrea Rinaldi, Daniela Capello, Marta Scandurra, et al.
Blood|November 15, 2011
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemiaDavide Rossi, Silvia Rasi, Giulia Fabbri, et al.
Haematologica|November 9, 2014
The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infectionLuca Arcaini, Davide Rossi, Marco Lucioni, et al.
The Lancet. Oncology|September 13, 2024
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialAlessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, et al.
Haematologica|December 31, 2011
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genesSimone Ferrero, Daniela Capello, Mirija Svaldi, et al.
Leukemia|June 25, 2021
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendationsWilliam G Wierda, Andrew Rawstron, Florence Cymbalista, et al.
American Journal of Hematology|November 4, 2017
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed casesMassimo Gentile, Tait D Shanafelt, Francesca R Mauro, et al.
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Blood|November 1, 2011
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractorinessDavide Rossi, Alessio Bruscaggin, Valeria Spina, et al.
Pageof 51

Showing results (381-390 of 504) with videos related to

Sort By:
Pageof 51
British Journal of Haematology|March 17, 2010
Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphomaAndrea Rinaldi, Daniela Capello, Marta Scandurra, et al.
Blood|November 15, 2011
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemiaDavide Rossi, Silvia Rasi, Giulia Fabbri, et al.
Haematologica|November 9, 2014
The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infectionLuca Arcaini, Davide Rossi, Marco Lucioni, et al.
The Lancet. Oncology|September 13, 2024
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialAlessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, et al.
Haematologica|December 31, 2011
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genesSimone Ferrero, Daniela Capello, Mirija Svaldi, et al.
Leukemia|June 25, 2021
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendationsWilliam G Wierda, Andrew Rawstron, Florence Cymbalista, et al.
American Journal of Hematology|November 4, 2017
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed casesMassimo Gentile, Tait D Shanafelt, Francesca R Mauro, et al.
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Blood|November 1, 2011
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractorinessDavide Rossi, Alessio Bruscaggin, Valeria Spina, et al.
Pageof 51